{
    "nct_id": "NCT04584112",
    "official_title": "A Phase Ib, Open-Label, Multicohort Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Patients With Triple-Negative Breast Cancer",
    "inclusion_criteria": "Inclusion Criteria\n\nCohort A:\n\n* Metastatic or locally advanced unresectable, histologically documented TNBC characterized by absence of human epidermal growth factor 2 (HER2), estrogen receptor (ER), and progesterone receptor (PR) expression\n* Only patients with metastatic TNBC tumors that are centrally tested and found to be programmed death-ligand 1 (PD-L1) positive will be enrolled\n* No prior chemotherapy or targeted systemic therapy for inoperable locally advanced or metastatic TNBC\n* Eastern Cooperative Oncology Group performance status of 0 or 1\n* Measurable disease, as assessed by the investigator according to RECIST v1.1\n* Adequate hematologic and end-organ function\n\nCohort B:\n\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Histologically documented TNBC (negative HER2, ER, and PR status)\n* Confirmed tumor PD-L1 evaluation as documented through central testing of a representative tumor tissue specimen\n* Primary breast tumor size of greater than (>) 2 centimeters (cm) by at least one radiographic or clinical measurement\n* Stage at presentation: cT2-cT4, cN0-cN3, cM0\n* Baseline left ventricular ejection fraction (LVEF) greater than or equal to (>/=) 53 percent (%) measured by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scans\n* Adequate hematologic and end-organ function\n\nExclusion Criteria\n\nCohort A:\n\n* Formalin-fixed, paraffin-embedded (FFPE) tumor tissue that is PD-L1 negative, as determined on the SP142 PD-L1 immunohistochemistry assay, with positivity defined as immune cells greater than or equal to (>/=) 1%\n* Spinal cord compression not definitively treated with surgery and/or radiation or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for >2 weeks prior to initiation of study treatment\n* Known central nervous system (CNS) disease, except for treated asymptomatic CNS metastases\n* Leptomeningeal disease\n\nCohort B:\n\n* History of invasive breast cancer\n* Stage IV (metastatic) breast cancer\n* Prior systemic therapy for treatment and prevention of breast cancer\n* Previous therapy with anthracyclines, platinum, or taxanes for any malignancy\n* Synchronous, bilateral invasive breast cancer\n* Cardiopulmonary dysfunction\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}